EP1351670A4 - Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda - Google Patents

Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda

Info

Publication number
EP1351670A4
EP1351670A4 EP01990191A EP01990191A EP1351670A4 EP 1351670 A4 EP1351670 A4 EP 1351670A4 EP 01990191 A EP01990191 A EP 01990191A EP 01990191 A EP01990191 A EP 01990191A EP 1351670 A4 EP1351670 A4 EP 1351670A4
Authority
EP
European Patent Office
Prior art keywords
methods
receptor antagonists
nmda receptor
neuropsychiatric disorders
treating neuropsychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01990191A
Other languages
German (de)
English (en)
Other versions
EP1351670A1 (fr
Inventor
Stuart M D Lipton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamas Pharmaceuticals Inc
Original Assignee
Neuromolecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuromolecular Inc filed Critical Neuromolecular Inc
Priority to EP07000173A priority Critical patent/EP1852113A3/fr
Publication of EP1351670A1 publication Critical patent/EP1351670A1/fr
Publication of EP1351670A4 publication Critical patent/EP1351670A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01990191A 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda Ceased EP1351670A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07000173A EP1852113A3 (fr) 2000-12-07 2001-12-07 Interface d'utilisateur pour contrôler de nombreux paramètres et procédé de contrôle de nombreux paramètres

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25400700P 2000-12-07 2000-12-07
US254007P 2000-12-07
PCT/US2001/048516 WO2002045710A1 (fr) 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07000173A Division EP1852113A3 (fr) 2000-12-07 2001-12-07 Interface d'utilisateur pour contrôler de nombreux paramètres et procédé de contrôle de nombreux paramètres

Publications (2)

Publication Number Publication Date
EP1351670A1 EP1351670A1 (fr) 2003-10-15
EP1351670A4 true EP1351670A4 (fr) 2004-07-07

Family

ID=22962564

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01990191A Ceased EP1351670A4 (fr) 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda

Country Status (8)

Country Link
EP (1) EP1351670A4 (fr)
JP (1) JP2004515477A (fr)
CN (1) CN1486180A (fr)
AU (1) AU2002229056A1 (fr)
BR (1) BR0116001A (fr)
CA (1) CA2436311A1 (fr)
MX (1) MXPA03005130A (fr)
WO (1) WO2002045710A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CA2569015A1 (fr) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Formulation de liberation modifiee de memantine
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
WO2007130724A2 (fr) 2006-02-06 2007-11-15 Northwind Ventures Systèmes et procédés de réduction de volume
JP5450053B2 (ja) * 2006-04-13 2014-03-26 ニューロテック ファーマシューティカルズ カンパニー リミテッド 細胞損傷及び炎症疾患の治療または予防用薬学組成物
RU2401263C2 (ru) * 2008-09-10 2010-10-10 Государственное образовательное учреждение высшего профессионального образования Самарский государственный технический университет Аминопроизводные адамантана, обладающие противовирусной активностью в отношении вируса гриппа
IT1396556B1 (it) 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
AU2010315535A1 (en) 2009-10-26 2012-05-03 Cardiokinetix, Inc. Ventricular volume reduction
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
JP5562716B2 (ja) 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN106687626B (zh) * 2014-04-30 2021-01-26 宇凤·简·曾 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
CN118290279A (zh) * 2014-05-29 2024-07-05 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物的盐
RU2017114607A (ru) 2014-09-28 2018-10-29 Кардиокинетикс, Инк. Устройства для терапии нарушений функции сердца
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
DE102018107407A1 (de) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen
ES3015758T3 (en) * 2017-08-01 2025-05-07 Stuart A Lipton Nitrosynapsin for use in treating autism spectrum disorder
AU2018372938B2 (en) * 2017-11-22 2025-04-10 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat CNS disorders
CN109206317B (zh) * 2018-09-12 2021-07-09 青岛海蓝医药有限公司 一种金刚烷胺类硝酸酯衍生物的制备工艺
CN110938006A (zh) * 2019-12-04 2020-03-31 重庆植恩药业有限公司 盐酸美金刚杂质c的制备方法
CN114544826B (zh) * 2020-11-24 2023-12-08 重庆医科大学 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005275A1 (fr) * 1992-09-03 1994-03-17 The Children's Medical Center Corporation Procede de prevention contre les lesions neuronales dues au recepteur nmda
WO1994006428A1 (fr) * 1992-09-22 1994-03-31 The Children's Medical Center Corporation Procede de prevention de deteriorations neuronales induites par le complexe recepteur nmda
WO2001062706A1 (fr) * 2000-02-22 2001-08-30 Panorama Research, Inc. Derives d'aminoadamantane convenant comme agents therapeutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584718A (ja) * 1981-06-30 1983-01-11 Nippon Chibagaigii Kk 新規適応症に用うる医薬製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005275A1 (fr) * 1992-09-03 1994-03-17 The Children's Medical Center Corporation Procede de prevention contre les lesions neuronales dues au recepteur nmda
WO1994006428A1 (fr) * 1992-09-22 1994-03-31 The Children's Medical Center Corporation Procede de prevention de deteriorations neuronales induites par le complexe recepteur nmda
WO2001062706A1 (fr) * 2000-02-22 2001-08-30 Panorama Research, Inc. Derives d'aminoadamantane convenant comme agents therapeutiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARSONS C G ET AL: "Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data", NEUROPHARMACOLOGY, vol. 38, no. 6, June 1999 (1999-06-01), pages 735 - 767, XP002279262, ISSN: 0028-3908 *
See also references of WO0245710A1 *
YAMADA KAZUO ET AL: "Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia", BIOLOGICAL PSYCHIATRY, vol. 41, no. 10, 1997, pages 1062 - 1064, XP002279263, ISSN: 0006-3223 *

Also Published As

Publication number Publication date
WO2002045710A1 (fr) 2002-06-13
EP1351670A1 (fr) 2003-10-15
JP2004515477A (ja) 2004-05-27
MXPA03005130A (es) 2004-12-06
BR0116001A (pt) 2004-07-06
AU2002229056A1 (en) 2002-06-18
WO2002045710A9 (fr) 2003-04-24
CN1486180A (zh) 2004-03-31
CA2436311A1 (fr) 2002-06-13

Similar Documents

Publication Publication Date Title
EP1351670A4 (fr) Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
IL152775A0 (en) Il-8 receptor antagonists
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
PL353854A1 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
IL157770A0 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
PL358584A1 (en) Cyclohexylamine derivative as subtype selective nmda receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
DZ3309A1 (en) Il-8 receptor antagonists
PL352232A1 (en) Il-8 receptor antagonists
IL161801A0 (en) Unsaturated amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists
EP1296958A4 (fr) Antagonistes des recepteurs nmda nr2b de l'iminopyrimidine
IL151431A0 (en) Il-8 receptor antagonists
ZA200104187B (en) 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists.
AU2002360819A8 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
EP1274415A4 (fr) Antagonistes du recepteur de il-8
AP2002002599A0 (en) Il-8 receptor antagonists
IL146046A0 (en) Il-8 receptor antagonists
EP1265905A4 (fr) Antagonistes du recepteur de l'interleukine 8 (il-8)
MXPA03003892A (es) Antagonistas del receptor bombesin.
EP1351687A4 (fr) Antagonistes des recepteurs de l'urotensine ii
EP1274413A4 (fr) Antagonistes du recepteur il-8
EP1263427A4 (fr) Antagonistes du recepteur de l'interleukine 8

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030707

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040526

17Q First examination report despatched

Effective date: 20050415

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WENT, GREGORY T.

Inventor name: LIPTON, STUART, M.D.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WENT, GREGORY T.

Inventor name: LIPTON, STUART, M.D.

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUROMOLECULAR INC.

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAZ Date of receipt of statement of grounds of appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDNOA3E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100806